A Phase 1, Open-label, Parallel-group Study to Assess The Effect Of CYP3A5 Genotype on the Pharmacokinetics of Maraviroc and CYP3A5-derived Metabolites With and Without Darunavir/Cobicistat In African-American and Caucasian Healthy Subjects

Trial Profile

A Phase 1, Open-label, Parallel-group Study to Assess The Effect Of CYP3A5 Genotype on the Pharmacokinetics of Maraviroc and CYP3A5-derived Metabolites With and Without Darunavir/Cobicistat In African-American and Caucasian Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Maraviroc (Primary) ; Cobicistat/darunavir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 11 Apr 2016 Status changed from recruiting to completed.
    • 23 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top